 CAMBRIDGE, Mass.--BUSINESS WIRE--Today, Sage Therapeutics, Inc. NASDAQ: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the first quarter ended March 31, 2021. Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises, and the progress weve made so far this year sets 